ALDH1A3 and neoplasm: Mechanistically, ALDH1A3 leads to drug resistance by detoxifying cytotoxic aldehydes that are generated during oxidative stress or chemotherapy, thereby protecting CSCs from apoptosis and enabling tumour recurrence [20].